Prediction of Childhood Epilepsy Outcome in Bangladesh
Information source: Institute of Child Health
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Epilepsy
Intervention: phenobarbitone (Drug); carbamazepine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Institute of Child Health Official(s) and/or principal investigator(s):
Brian Neville, Professor, Principal Investigator, Affiliation: Institute of Child Health
Selina Banu, Dr, Principal Investigator, Affiliation: Children’s Hospital Dhaka (Shishu) Bangladesh.
Summary
Randomised controlled trial of the use of phenobarbitone and carbamazepine in childhood
epilepsy in Bangladesh with particular reference to behavioural side effects.
Clinical Details
Study design: Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 2 Years.
Maximum age: 16 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Active epilepsy
- Aged 2-15 years
Exclusion Criteria:
- Excluded absence
- Myoclonic and malignant epilepsy syndromes
- Major motor and cognitive impairments
- Those currently receiving antiepilepsy drugs.
Locations and Contacts
Children’s Hospital Dhaka (Shishu) Bangladesh., Sher-e-Bangla Nagar, Dhaka 1207, Bangladesh
Institute of Child Health, London WC1N 1EH, United Kingdom
Additional Information
Last updated: December 22, 2006
|
